Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations

Y. Shapira; A. Weinberger; A. J. Wysenbeek

doi:10.1007/BF02230354

Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations

Y. Shapira^*, A. Weinberger, A. J. Wysenbeek

^*Corresponding author for this work

Rabin Medical Center Israel

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

Lymphadenopathy (LAP) is a frequent sign in systemic lupus erythematosus (SLE). Yet, data concerning its relation to the various disease manifestations are scarce or absent. LAP was present in 23/90 (26%) SLE patients. Patients with LAP had significantly more constitutional symptoms of fatigue, fever and weight loss, more cutaneous symptoms and signs, a higher rate of hepatomegaly and splenomegaly, increased anti-dsDNA antibodies and decreased complement levels. Disease activity index was higher among patients with LAP, as was the intake of steroids and antimalaria medications. There was no difference in renal or central nervous system (CNS) involvement between patients with LAP and those without LAP.

Original language	English
Pages (from-to)	335-338
Number of pages	4
Journal	Clinical Rheumatology
Volume	15
Issue number	4
DOIs	https://doi.org/10.1007/BF02230354
State	Published - Jul 1996
Externally published	Yes

Keywords

Lymphadenopathy
Systemic lupus erythematosus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02230354

Cite this

@article{828b478dc321470e88a9c07e244e84d6,

title = "Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations",

abstract = "Lymphadenopathy (LAP) is a frequent sign in systemic lupus erythematosus (SLE). Yet, data concerning its relation to the various disease manifestations are scarce or absent. LAP was present in 23/90 (26%) SLE patients. Patients with LAP had significantly more constitutional symptoms of fatigue, fever and weight loss, more cutaneous symptoms and signs, a higher rate of hepatomegaly and splenomegaly, increased anti-dsDNA antibodies and decreased complement levels. Disease activity index was higher among patients with LAP, as was the intake of steroids and antimalaria medications. There was no difference in renal or central nervous system (CNS) involvement between patients with LAP and those without LAP.",

keywords = "Lymphadenopathy, Systemic lupus erythematosus",

author = "Y. Shapira and A. Weinberger and Wysenbeek, {A. J.}",

year = "1996",

month = jul,

doi = "10.1007/BF02230354",

language = "אנגלית",

volume = "15",

pages = "335--338",

journal = "Clinical Rheumatology",

issn = "0770-3198",

publisher = "Springer London",

number = "4",

}

TY - JOUR

T1 - Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations

AU - Shapira, Y.

AU - Weinberger, A.

AU - Wysenbeek, A. J.

PY - 1996/7

Y1 - 1996/7

N2 - Lymphadenopathy (LAP) is a frequent sign in systemic lupus erythematosus (SLE). Yet, data concerning its relation to the various disease manifestations are scarce or absent. LAP was present in 23/90 (26%) SLE patients. Patients with LAP had significantly more constitutional symptoms of fatigue, fever and weight loss, more cutaneous symptoms and signs, a higher rate of hepatomegaly and splenomegaly, increased anti-dsDNA antibodies and decreased complement levels. Disease activity index was higher among patients with LAP, as was the intake of steroids and antimalaria medications. There was no difference in renal or central nervous system (CNS) involvement between patients with LAP and those without LAP.

AB - Lymphadenopathy (LAP) is a frequent sign in systemic lupus erythematosus (SLE). Yet, data concerning its relation to the various disease manifestations are scarce or absent. LAP was present in 23/90 (26%) SLE patients. Patients with LAP had significantly more constitutional symptoms of fatigue, fever and weight loss, more cutaneous symptoms and signs, a higher rate of hepatomegaly and splenomegaly, increased anti-dsDNA antibodies and decreased complement levels. Disease activity index was higher among patients with LAP, as was the intake of steroids and antimalaria medications. There was no difference in renal or central nervous system (CNS) involvement between patients with LAP and those without LAP.

KW - Lymphadenopathy

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0029973801&partnerID=8YFLogxK

U2 - 10.1007/BF02230354

DO - 10.1007/BF02230354

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0029973801

SN - 0770-3198

VL - 15

SP - 335

EP - 338

JO - Clinical Rheumatology

JF - Clinical Rheumatology

IS - 4

ER -

Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this